Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

20254 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov, NCT04505826 . Registered August 6, 2020.

Good health and well-being

Published in: Breast Cancer Research

Volume 27, Issue 1, pp. 119-119

Field-Weighted Citation Impact: 6.07